Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Overview of attention for article published in Clinical Cancer Research, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

So far, Altmetric has seen 14 tweets from 14 users, with an upper bound of 31,977 followers.

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

RT @PTarantinoMD: Interesting biomarker analysis from WSG-ADAPT HER2+/HR-. ERBB2, ER and immune-response signatures were associsted w/ pCR…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 10 additional tweets.